Posts

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

Authors: Marcus A. Bachhuber, Brendan Saloner, Chinazo O. Cunningham, et al
JAMA Internal Medicine, October 2014

IMPORTANCE: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mort…

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…

PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.

Authors: George R. Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs, January-March 2014

BACKGROUND: New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case reports, of the effects of cannabis on PTSD symptoms. The purpose of the study was to report…

A controlled family study of cannabis users with and without psychosis.

Authors: Ashley C. Proal, Jerry Fleming, Juan A. Galvez-Buccollini, Lynn E. DeLisi
Schizophrenia Research, January 2014

BACKGROUND: Cannabis is one of the most highly abused illicit drugs in the world. Several studies suggest a link between adolescent cannabis use and schizophrenia. An understanding of this link would have significant implications for legalization of cannabis and its medicinal…

Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors: Wilfrid Noel Raby, Kenneth M. Carpenter, Jami Rothenberg, Adam C. Brooks, Huiping Jiang, et al
American Journal on Addictions, July/August 2009

Naltrexone is a theoretically promising alternative to agonist substitution treatment for opioid dependence, but its effectiveness has been severely limited by poor adherence. This study examined, in an independent sample, a previously observed association between moderate can…

Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.

Authors: A Neumeister, M D Normandin, R H Pietrzak, D Piomelli, M Q Zheng, A Gujarro-Anton, et al
Molecular Psychiatry, September 2013

Endocannabinoids and their attending cannabinoid type 1 (CB1) receptor have been implicated in animal models of post-traumatic stress disorder (PTSD). However, their specific role has not been studied in people with PTSD. Herein, we present an in vivo imaging study using posit…

The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD).

Post-traumatic stress disorder (PTSD) is a psychiatric disorder of significant prevalence and morbidity, whose pathogenesis relies on paradoxical changes of emotional memory processing. An ideal treatment would be a drug able to block the pathological over-consolidation and continuous retrieval of the traumatic event, while enhancing its extinction and reducing the anxiety symptoms.

Survey of Psychiatrists On Medical Cannabis

Psychiatric Times invited psychiatrists to complete a survey about medicinal marijuana and didn’t expect nearly 2200 people to complete that survey in just a few days. The results, reported in the July 2013 issue, reflect the current state of confusion among medical professionals regarding medical cannabis.

Medical Marijuana Laws, Traffic Fatalities, and Alcohol Consumption

Authors: D. Mark Anderson, Benjamin Hansen, Daniel I. Rees
The Journal of Law and Economics, May 2013

To date, 19 states have passed medical marijuana laws, yet very little is known about their effects. The current study examines the relationship between the legalization of medical marijuana and traffic fatalities, the leading cause of death among Americans ages 5–34. The firs…

Does using marijuana increase the risk for developing schizophrenia?

Authors: A. Eden Evins, Alan I. Green, John M. Kane, Sir Robin M. Murray
The Journal of Clinical Psychiatry, April 2013

As more US states and other countries consider legalizing marijuana, clinicians need to know the possible effects of this drug. Research has shown a connection between marijuana use and an increased risk for schizophrenia in young people who are vulnerable to developing psycho…

Prenatal substance abuse: short- and long-term effects on the exposed fetus.

Authors: Marylou Behnke, Vincent C. Smith, COMMITTEE ON SUBSTANCE ABUSE, COMMITTEE ON FETUS AND NEWBORN
Pediatrics, March 2013

Prenatal substance abuse continues to be a significant problem in this country and poses important health risks for the developing fetus. The primary care pediatrician’s role in addressing prenatal substance exposure includes prevention, identification of exposure, recognition…

Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: association with wrist cutting as impulsive self-injurious behavior.

Authors: Marc Schroeder, Christian Eberlein, Martina de Zwaan, Johannes Kornhuber, Stefan Bleich, Helge Frieling
Psychoneuroendocrinology, December 2012

The cannabinoid 1 (CB 1) receptor as the primary mediator of the endocannabinoid (EC) system was found to play a role in eating disorders (EDs), depression, anxiety, and suicidal behavior. The CB 1 receptor is assumed to play a crucial role in the central reward circuitry with…